FDA Warns That Hep C Meds Can Reactivate Hep B
The U.S. Food and Drug Administration on Tuesday said it's requiring boxed warnings on hepatitis C medications called direct-acting antivirals, including Gilead Sciences Inc.'s Harvoni and Sovaldi and AbbVie Inc.'s Viekira...To view the full article, register now.
Already a subscriber? Click here to view full article